Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today provided an interim analysis from its ongoing phase 1B trial of Next Generation Capecitabine (“NGC-Cap”) in patients with gastrointestinal cancer, which identifies a … Continue reading InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Encouraging Results on Potential Cancer Treatment Approach